US 9896445
Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer
granted A61KA61K31/443A61K31/4439
Quick answer
US patent 9896445 (Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancer) held by Ansana BioSciences, LLC expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Ansana BioSciences, LLC
- Grant date
- Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 27
- CPC classes
- A61K, A61K31/443, A61K31/4439, A61K31/444, A61K31/506